Mike Machaba Sathekge

← Back to University of Pretoria

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth

   2018 · 370 citations

2. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study

   2018 · 354 citations

3. Antimicrobial Peptides: Their Role as Infection-Selective Tracers for Molecular Imaging

   2014 · 225 citations

4. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

   2021 · 219 citations

5. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

   2024 · 203 citations

6. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225 Ac-PSMA-617 Radioligand Therapy

   2019 · 193 citations

7. 68Ga-FAPI-PET/CT in patients with various gynecological malignancies

   2021 · 181 citations

8. Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study

   2017 · 179 citations

9. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours

   2012 · 159 citations

10. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer

    2017 · 147 citations

11. Radiotherapy and theranostics: a Lancet Oncology Commission

    2024 · 146 citations

12. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

    2020 · 126 citations

13. PET/CT imaging of Mycobacterium tuberculosis infection

    2016 · 124 citations

14. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area

    2010 · 123 citations

15. 68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?

    2018 · 123 citations

16. Advances in imaging of tuberculosis

    2014 · 120 citations

17. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients

    2016 · 120 citations

18. FDG-PET Imaging in HIV Infection and Tuberculosis

    2013 · 113 citations

19. EANM/SNMMI guideline/procedure standard for [18F]FDG hybrid PET use in infection and inflammation in adults v2.0

    2024 · 98 citations

20. Tuberculosis

    2017 · 95 citations

21. COVID-19 pandemic: guidance for nuclear medicine departments

    2020 · 94 citations

22. Use of 18F-FDG PET to Predict Response to First-Line Tuberculostatics in HIV-Associated Tuberculosis

    2011 · 89 citations

23. Extraordinary arousal from semi-comatose state on zolpidem. A case report.

    2000 · 87 citations

24. Preclinical Evaluation of 68Ga-Labeled 1,4,7-Triazacyclononane-1,4,7-Triacetic Acid-Ubiquicidin as a Radioligand for PET Infection Imaging

    2014 · 85 citations

25. Development and Prospects of Dedicated Tracers for the Molecular Imaging of Bacterial Infections

    2013 · 84 citations

← Return to the university profile